Savić Miroslav M, Milinković Marija M, Rallapalli Sundari, Clayton Terry, Joksimović Sroan, Van Linn Michael, Cook James M
Department of Pharmacology, Faculty of Pharmacy, University of Belgrade, Belgrade, Serbia.
Int J Neuropsychopharmacol. 2009 Oct;12(9):1179-93. doi: 10.1017/S1461145709000108. Epub 2009 Mar 6.
The clinical use of benzodiazepines (BZs) is hampered by sedation and cognitive deterioration. Although genetic and pharmacological studies suggest that alpha1- and alpha5-containing GABA(A) receptors mediate and/or modulate these effects, their molecular substrate is not fully elucidated. By the use of two selective ligands: the alpha1-subunit affinity-selective antagonist beta-CCt, and the alpha5-subunit affinity- and efficacy-selective antagonist XLi093, we examined the mechanisms of behavioural effects of diazepam in the tests of spontaneous locomotor activity and water-maze acquisition and recall, the two paradigms indicative of sedative- and cognition-impairing effects of BZs, respectively. The locomotor-activity decreasing propensity of diazepam (significant at 1.5 and 5 mg/kg) was antagonized by beta-CCt (5 and 15 mg/kg), while it tended to be potentiated by XLi093 in doses of 10 mg/kg, and especially 20 mg/kg. Diazepam decreased acquisition and recall in the water maze, with a minimum effective dose of 1.5 mg/kg. Both antagonists reversed the thigmotaxis induced by 2 mg/kg diazepam throughout the test, suggesting that both GABA(A) receptor subtypes participate in BZ effects on the procedural component of the task. Diazepam-induced impairment in the declarative component of the task, as assessed by path efficiency, the latency and distance before finding the platform across acquisition trials, and also by the spatial parameters in the probe trial, was partially prevented by both, 15 mg/kg beta-CCt and 10 mg/kg XLi093. Combining a BZ with beta-CCt results in the near to control level of performance of a cognitive task, without sedation, and may be worth testing on human subjects.
苯二氮䓬类药物(BZs)的临床应用受到镇静作用和认知功能衰退的限制。尽管遗传学和药理学研究表明,含α1和α5的γ-氨基丁酸A(GABA(A))受体介导和/或调节这些作用,但其分子机制尚未完全阐明。通过使用两种选择性配体:α1亚基亲和力选择性拮抗剂β-CCt和α5亚基亲和力及效能选择性拮抗剂XLi093,我们在自发运动活性测试以及水迷宫获取和记忆测试中研究了地西泮行为效应的机制,这两种范式分别指示了BZs的镇静和认知损害作用。地西泮降低运动活性的倾向(在1.5和5 mg/kg时显著)被β-CCt(5和15 mg/kg)拮抗,而XLi093在10 mg/kg尤其是20 mg/kg剂量时倾向于增强这种作用。地西泮降低了水迷宫中的获取和记忆能力,最小有效剂量为1.5 mg/kg。在整个测试过程中,两种拮抗剂均逆转了2 mg/kg地西泮诱导的趋触性,表明两种GABA(A)受体亚型均参与了BZ对任务程序部分的影响。通过路径效率、在获取试验中找到平台之前的潜伏期和距离以及在探测试验中的空间参数评估,地西泮对任务陈述性部分的损害被15 mg/kg的β-CCt和10 mg/kg的XLi093部分阻止。将BZ与β-CCt联合使用可使认知任务的表现接近对照水平,且无镇静作用,可能值得在人类受试者上进行测试。